Detailed Information on Publication Record
2015
Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience
KISSOVÁ, Jarmila, Petra OVESNÁ, Alena BULIKOVÁ, Jiřina ZAVŘELOVÁ, Miroslav PENKA et. al.Basic information
Original name
Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience
Authors
KISSOVÁ, Jarmila (203 Czech Republic, guarantor, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Alena BULIKOVÁ (203 Czech Republic, belonging to the institution), Jiřina ZAVŘELOVÁ (203 Czech Republic) and Miroslav PENKA (203 Czech Republic, belonging to the institution)
Edition
BLOOD COAGULATION & FIBRINOLYSIS, Philadelphia, Lippincott Williams & Wilkins, 2015, 0957-5235
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 1.242
RIV identification code
RIV/00216224:14110/15:00083018
Organization unit
Faculty of Medicine
UT WoS
000353828800016
Keywords in English
microparticle; myeloproliferative neoplasms; procoagulant activity; thrombosis
Tags
Tags
International impact, Reviewed
Změněno: 2/6/2015 09:36, Ing. Mgr. Věra Pospíšilíková
Abstract
V originále
Microparticles are small membrane fragments with dimension between 0.1 and 1 mu m, which are released during cell activation or apoptosis, exposing the phospholipid phosphatidylserine and membrane antigens typical for cellular origin. Philadelphia-negative myeloproliferative neoplasms (MPNs) are characterized by an increased risk of thrombosis. Data from literature suggest an association between thrombosis and the procoagulant activity of microparticles. Association between the procoagulant activity of microparticles and the incidence of thrombosis was assesed in a group of 126 patients with Philadelphia-negative MPNs. Measurement of microparticles procoagulant activity was performed using a functional assay, namely the Zymuphen MP-activity (Hyphen Biomed, Neuville-sur-oise, France). A total of 539 samples were analysed within this group of patients, regardless of patients' state of health. A significantly higher circulating microparticles procoagulant activity was found in MPN patients as compared with the control group (P<0.001). A pathological level of procoagulant activity was observed more frequently in patients with polycythaemia vera (88%, P=0.002) than groups of patients with essential thrombocythaemia (73.2%) and primary myelofibrosis (68.3%); the same result was confirmed in patients with a history of venous thrombosis in comparison with patients without thrombosis (84.7 vs. 73.2%, P=0.029). Patients without cytoreductive treatment had a higher activity of microparticles (P=0.010). Furthermore, presence of JAK2 V617F mutation was associated with an increased procoagulant activity (P=0.007), as well as the higher JAK2 V617F allele burden (P=0.001). Further prospective clinical studies will be necessary to evaluate the clinical relevance of microparticles in the prediction hypercoagulable state in these patients.
Links
| MUNI/A/0723/2012, interní kód MU |
|